Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript Summary
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript Summary
Cellectis announced the initiation of R&D activities for three new programs under a collaboration with AstraZeneca, focusing on different CAR T therapies and gene therapies.The following is a summary of the Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript:
以下是Cellectis S.A. (CLLS) 2024年第三季度業績會議呼叫交易記錄摘要:
Financial Performance:
財務表現:
Cellectis reported significant financial progress, with $47 million triggered under the AstraZeneca joint research and collaboration agreement; $25 million upfront and $22 million from reaching development milestones.
Cash, cash equivalents, and short-term deposits total $264 million as of September 30th, 2024, up from $156 million at the end of 2023, largely due to a $140 million investment from AstraZeneca, a $16 million disbursement from the European Investment Bank, and $27 million revenue, offset by various payments.
Cellectis報告了顯著的財務進展，根據阿斯利康聯合研究與合作協議觸發了4700萬美元；其中前期款2500萬美元，達到開發里程碑2200萬美元。
截至2024年9月30日，現金、現金等價物和短期存款總額爲26400萬美元，較2023年底的15600萬美元增加，主要是由於阿斯利康的14000萬美元投資，歐洲投資銀行的1600萬美元撥款，和2700萬美元營業收入帶來的收入，抵消了各種支付。
Business Progress:
業務進展:
Cellectis announced the initiation of R&D activities for three new programs under a collaboration with AstraZeneca, focusing on different CAR T therapies and gene therapies.
The company has decided to prioritize the development of UCART22 in BALLI-01 and UCART20x22 in NATHALI-01 studies, while de-prioritizing the development of UCART123 in AMELI-01.
Expect to reveal data for Phase I in 2025 and maintain a focus on these strategic clinical trials.
Cellectis宣佈在與阿斯利康的合作框架下啓動了三個新項目的研發活動，重點放在不同的CAR T療法和基因療法上。
該公司決定優先發展BALLI-01中的UCART22和NATHALI-01研究中的UCART20x22，同時將UCART123在AMELI-01的開發降至次要。
預計2025年公佈第一期數據，並繼續專注於這些戰略臨床試驗。
Opportunities:
機會：
Strategic collaboration with AstraZeneca to advance cell and gene therapy capabilities, triggering significant investment and partnership benefits.
Focus on UCART22 and UCART20x22 trials indicates potential high-impact therapeutic options in hematological malignancies.
與阿斯利康展開戰略合作，推動電芯和基因治療能力的發展，帶來重大的投資和合作夥伴關係利益。
專注於UCART22和UCART20x22的試驗表明在血液惡性腫瘤中具有潛在高影響力的治療開空。
Risks:
風險：
De-prioritization of UCART123 in acute myeloid leukemia (AML) due to strategic reallocation of resources, reflecting the company's need to focus on the most promising trials potentially affecting other projects.
由於資源戰略性重新分配，導致骨髓母細胞性白血病（AML）中UCART123的降低優先級，反映出公司需要專注於最有希望的試驗，可能影響其他項目。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
